Related MeSH Hierarchy (5)
Diseases [C] » Infections [C01] » Virus Diseases » RNA Virus Infections » Nidovirales Infections » Coronaviridae Infections » Coronavirus Infections » COVID-19
Diseases [C] » Infections [C01] » Respiratory Tract Infections » Pneumonia » Pneumonia, Viral » COVID-19
Diseases [C] » Infections [C01] » Virus Diseases » Pneumonia, Viral » COVID-19
Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Pneumonia » Pneumonia, Viral » COVID-19
Diseases [C] » Respiratory Tract Diseases [C08] » Respiratory Tract Infections » Pneumonia » Pneumonia, Viral » COVID-19
Description
A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. MeSH
Hierarchy View
Subtype Terms (1)
Post-Acute COVID-19 Syndrome
27 drugs (14 approved, 13 experimental)
Phase 4 Indicated Drugs (138)
20-valent pneumococcal conjugate vaccine (Prevnar 20)
23-valent pneumococcal polysaccharide vaccine (pneumovax-23)
bismuth subsalicylate (Pepto-Bismol)
bivalent oral polio vaccine (bopv), type 1 and type 3 (BOPV)
immune globulin (human) (Gamastan)
inactivated rabies vaccine (Imovax)
interferon alpha-2b (Intron-A)
interferon beta-1b (betaseron)
measles, mumps, and rubella vaccine (MMR)
peginterferon beta-1a (Plegridy)
pneumococcal 13-valent conjugate vaccine (prevnar 13)
Phase 3 Indicated Drugs (253)
acetylsalicylic acid (aspirin)
alpha-1 antitrypsin (Prolastin)
Bacterial Lysates (pulmonarom)
bibp omicron inactivated covid-19 vaccine (vero cell)
bivalent mrna-1273 (Spikevax bivalent)
bivalent recombinant covid-19 vaccine (adenovirus type 5 vector)
double-stranded rna sodium salt
human fecal microbiota (Reybota)
human papillomavirus 9-valent vaccine, recombinant (Gardasil 9)
liposomed heat-inactivated mycobacterium tuberculosis bacilli
Mesenchymal Stem Cell Secretome
omicron covid-19 vaccine (vero cell), inactivated
sars-cov-2 adjuvanted recombinant protein vaccine (bivalent)
sars-cov-2 adjuvanted recombinant protein vaccine (monovalent)
sars-cov-2 fusion protein vaccine
sars-cov-2 protein subunit recombinant vaccine PT Biopharma
sulfur hexafluoride lipid-type a microspheres (Lumason)
tenofovir alafenamide (genvoya)
Tetanus and diphtheria toxoids adsorbed (Decavac)
tetravalent influenza virus lysis vaccine
two-component covid-19 vaccine (cho cell)
tyrosyl-d-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate
Phase 2 Indicated Drugs (311)
allogeneic adipose derived mesenchymal stem cell
allogeneic cardiosphere-derived cells
antithrombin iii (human) (thrombate iii)
Aspartyl-alanyl-diketopiperazine (Ampion)
autologous mesenchymal stem cells
interferon alfacon-1 (Infergen)
Mesenchymal Stem Cells Exosomes
recombinant novel coronavirus vaccine (adenovirus type 5 vector)
Phase 1 Indicated Drugs (150)
multi-virus-specific cytotoxic t lymphocytes
partially hla-matched virus specific t cells
Other Experimental Indicated Drugs (70)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
